MAPK11 and cancer: One of the most prominent is the p38α and p38β inhibitor LY2228820/Ralimetinib, which has antiangiogenic effects in vitro and in vivo [150] and has been tested in a phase I study in combination with tamoxifen in patients with advanced cancer [151].